Innovative

The NHS is central to this vision. As a key innovation partner to industry, combining deep clinical expertise, trial and deployment platforms at scale, with longitudinal data from a diverse population of more than 65 million people. With 1.6 million patient interactions every 24 hours, an unparalleled level of information is generated alongside the routine business of delivering care – no other healthcare system in the world offers this level of insight into our health. We want to work with the global life sciences sector to maximise the potential of the NHS as a partner to enable and accelerate research and innovation.

Our science and universities are renowned – with 4 of the Top 10 universities in the world for life sciences and medicine – and a pipeline of new talent on the horizon. The UK Biobank continues to be a unique research and discovery resource for the world, while Our Future Health will bring together up to five million people to develop new ways to prevent, detect and treat diseases.

The industry is maturing, with more than 282,000 people employed across the UK in more than 6,500 life sciences businesses, and sector turnover grew to £94 billion in 2021. The world’s Top 25 biopharma companies all operate in the UK, and the UK ecosystem offers an expert services and supply chain across the lifecycle of product development and delivery.

The combination of Government support, unparalleled science, access to the world’s largest single healthcare system, and the deepest capital markets in Europe have created an environment where biotechs can thrive. More than any single US city, London sits at the confluence of tech, bio and finance. This is why the UK is home to 1 in 3 biotechs founded in Europe in the last decade, and holds the leading position in Europe for life sciences finance, accounting for more than a third of total venture capital raised and over half of the total deals recorded in 2022.

Pair this collaborative ecosystem with an improving business environment, clinical trials and regulation, and with the UK’s extensive global network and influence and you have a highly competitive life sciences investment destination, and strong foundation for export.